HIV Therapy Advancements: Promising Results fro...

By HEOR Staff Writer

November 14, 2025

Breakthrough Single-Tablet Regimen Drives HIV Therapy Advancements Gilead Sciences has announced promising topline results from the Phase 3 ARTISTRY-1 trial, demonst...

Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurem...

Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk ...

ViiV Healthcare Licensing: Expanding Access to Long-Acting HIV Treatment in L...

ARVs Water Impact: Examining the Environmental Consequences of Antiretroviral...

Lenacapavir HIV Prevention: Gilead’s Strategic Agreement to Enhance Acc...

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Pr...

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

Cost-Effective HIV PrEP: CAB-LA Transforms Prevention

Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries

HIV Colorectal Cancer Survival

CKD Prevalence in HIV Patients on TDF: A Global Perspective

New Global AIDS Strategy 2030 Aims to End AIDS Threat by 2030